Weight Loss Medications · Tool Face-Off

Ozempic vs Zepbound

Quick answer

Both are weekly injectables that crush appetite, but Zepbound's dual-hormone action delivers more weight loss on average. Ozempic wins on longer real-world track record and wider insurance coverage.

Our pick

Ozempic

The OG GLP-1 that started the weight-loss injection craze

4★

Zepbound

The dual-action newcomer that out-shrinks almost everything

3.8★

Active Ingredient

Semaglutide (GLP-1 agonist)

Tirzepatide (GLP-1 + GIP dual agonist)

FDA Approval for Weight Loss

No (approved for T2D; Wegovy is the weight-loss twin)

Yes — FDA approved for chronic weight management (2023)

Average Weight Loss (Clinical Trials)

~15% body weight (STEP trials, 2.4mg Wegovy dose)

~20–22% body weight (SURMOUNT-1, highest dose)

Dosing Range

0.5 mg, 1 mg, 2 mg weekly

2.5 mg → up to 15 mg weekly

List Price (without insurance)

~$900–$1,000/month

~$1,060–$1,100/month

Manufacturer Savings Card

Novo Nordisk card: as low as $25/month (eligible patients)

Lilly savings card: as low as $25/month (eligible patients)

Cardiovascular Outcome Trial

SUSTAIN-6 & SELECT — proven CV risk reduction

SURMOUNT-MMO ongoing; CV data still maturing

Years on Market

Since 2017 (~7 years of real-world data)

Since 2023 (~1–2 years of real-world data)

Primary FDA Indication

Type 2 Diabetes management

Chronic weight management (obesity/overweight + comorbidity)

Common GI Side Effects

Nausea, vomiting, diarrhea — moderate frequency

Similar GI profile; some data suggest slightly better tolerance

Injection Device

Pre-filled FlexTouch pen, single-use

Pre-filled auto-injector pen, single-use

Insurance Coverage for Weight Loss

Often covered for T2D; Wegovy form needed for obesity coverage

Growing coverage but still denied by many plans

Ozempic

Ease of Use★★★★☆

Long-Term Data★★★★½

Insurance Coverage★★★★☆

Weight Loss Efficacy★★★½☆

Side Effect Tolerance★★★½☆

Cardiovascular Benefits★★★★½

Zepbound

Ease of Use★★★★☆

Long-Term Data★★★☆☆

Insurance Coverage★★★☆☆

Weight Loss Efficacy★★★★★

Side Effect Tolerance★★★½☆

Cardiovascular Benefits★★★★☆

Worth knowing

Zepbound's 22% average weight loss in trials is nearly double what older weight-loss drugs could achieve.
Ozempic's SELECT trial showed a 20% reduction in major cardiovascular events — a huge deal beyond just blood sugar.
Both drugs work by slowing gastric emptying, which is why that 'food noise' in your head gets eerily quiet.
The U.S. spends more on GLP-1 drugs than on any other drug class — demand has caused repeated supply shortages of both.
Stopping either medication typically leads to regaining most lost weight within a year, making these long-term commitments.

Semaglutide (Ozempic's ingredient) was originally discovered by studying the saliva of a Gila monster. Yes, a lizard is responsible for one of the most prescribed drugs on Earth.

If you want

You want maximum weight loss and have obesity as your primary concern

Zepbound's dual GLP-1 + GIP mechanism consistently delivers 5–7% more body weight loss than semaglutide in head-to-head data.

→ Pick Zepbound

If you want

You have Type 2 Diabetes AND cardiovascular disease

Ozempic has years of proven cardiovascular outcome data and is directly FDA-approved for T2D with heart disease risk reduction.

→ Pick Ozempic

If you want

You're worried about insurance coverage and out-of-pocket cost

Ozempic's longer market presence means more insurers have established coverage pathways, especially for diabetic patients.

→ Pick Ozempic